 Kodiak Sciences Inc NASDAQ: KOD announced new data from one-year durability, efficacy, and safety data from the ongoing Phase 1b study evaluating KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degeneration wet AMD diabetic macular edema DME and retinal vein occlusion RVO. Kodiak presented the data at the Angiogenesis, Exudation, and Degeneration 2021 Annual Meeting. 